OrbiMed Reveals 8.9% Stake in BlossomHill Post-IPO, Alongside Board Influence and Registration Rights

summarizeSummary

OrbiMed Advisors disclosed an 8.9% stake in BlossomHill Therapeutics after the IPO, including board representation and registration rights, with shares locked up for 180 days.

check_boxKey Events · Ownership and Investor Activity · BLSM

• OrbiMed Holds 8.9% Stake

  OrbiMed Advisors and OrbiMed Capital GP VIII LLC beneficially own 2,714,279 shares (8.9%) of BlossomHill, based on 30,643,660 shares outstanding.

• IPO Purchases and Conversions

  Stake includes 1,039,996 Series A and 1,049,283 Series B preferred shares converted 1-for-1 at IPO, plus 625,000 shares bought at $16.00 in the IPO.

• Board Representation

  Carl L. Gordon, an OrbiMed member, serves on BlossomHill's board and must transfer any equity compensation to OrbiMed/OPI VIII.

• Registration Rights and Lock-Up

  OrbiMed holds demand, piggyback, and S-3 registration rights; shares are subject to a 180-day lock-up expiring in early February 2027.

auto_awesomeAnalysis · BLSM · Life Sciences

Following BlossomHill Therapeutics' August 10 IPO, pre-IPO backer OrbiMed Advisors now controls 2,714,279 shares, or 8.9% of the company. That position includes 1,039,996 Series A and 1,049,283 Series B preferred shares converted one-for-one at the offering, plus 625,000 shares acquired at $16.00. Board representation comes via Carl L. Gordon, an OrbiMed member, giving the firm a voice in governance. The filing also details registration rights and a 180-day lock-up, meaning OrbiMed cannot sell until early February 2027. While this is a notable ownership disclosure from a sophisticated healthcare investor, it largely consolidates previously reported IPO purchases.